Erik J Asmus

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Deborah A. Bowen, A. Feldman, T. Habermann, 2017, Blood.

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

J. Copland, N. Foster, S. Weroha, 2020, ESMO Open.

Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab

E. Winer, L. Carey, H. Rugo, 2020, Clinical Cancer Research.

Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers.

J. Copland, N. Foster, S. Weroha, 2019, Journal of Clinical Oncology.

A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.

Minetta C. Liu, M. Rivera, J. Kasperbauer, 2019, Thyroid : official journal of the American Thyroid Association.

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

A. Jakubowiak, Shaji K. Kumar, B. Laplant, 2022, Blood.

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Deborah A. Bowen, A. Feldman, T. Habermann, 2016 .

PD-1 Blockade with Pembrolizumab in Relapsed Low Grade Non-Hodgkin Lymphoma

A. Feldman, T. Habermann, D. Northfelt, 2017 .